References
- Rodriguez-Merchan EC. Prevention of the musculoskeletal complications of hemophilia. Adv Prev Med 2012; 2012: 201271. doi: 10.1155/2012/201271.
- Van den Berg HM, Fisher K. Phenotypic-genotypic relationship. In: Lee CA, Berntorp EE, Hoots WK (ed.). Textbook of Haemophilia. 2nd ed. Chichester: Wiley-Blackwell, 2010: 33–7.
- Berntorp E, Shapiro AD. Modern haemophilia care. Lancet 2012; 379: 1447–56. doi: 10.1016/S0140-6736(11)61139-2.
- Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet 2003; 361: 1801–9. doi: 10.1016/S0140-6736(03)13405-8.
- Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of haemophilia, 3rd edition. Haemophilia 2020; 00: 1–158. doi: 10.1111/hae.14046.
- EURORDIS Rare Diseases Europe. About orphan drugs. Available from http://www.eurordis.org/aboutorphan-drugs. (accessed 28 September 2020).
- Mannucci PM. Back to the future: a recent history of haemophilia treatment. Haemophilia 2008; 14(Suppl 3): 10–18. doi: 10.1111/j.1365-2516.2008.01708.x.
- Franchini M. The modern treatment of haemophilia: a narrative review. Blood Transfus 2013; 11(2): 178–82. doi: 10.2450/2012.0166-11.
- Carcao MD. The diagnosis and management of congenital hemophilia. Semin Thromb Hemost 2012; 38(7): 727–34. doi: 10.1055/s-0032-1326786.
- Keeling D, Tait C, Makris M. Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. A United Kingdom Haemophilia Center Doctors’ Organisation (UKHCDO) guideline approved by the British Committee for Standards in Haematology. Haemophilia 2008; 14(4): 671–84. doi: 10.1111/j.1365-2516.2008.01695.x.
- Kodra Y, Cavazza M, Schieppati A, et al. The social burden and quality of life of patients with haemophilia in Italy. Blood Transfus 2014; 12(Suppl 3): s567–75. doi:10.2450/2014.0042-14s.
- Henrard S, Devleesschauwer B, Beutels P, et al. The health and economic burden of haemophilia in Belgium: a rare, expensive and challenging disease. Orphanet J Rare Dis 2014; 9: 39. doi: 10.1186/1750-1172-9-39.
- Markova I, McDonald K, Forbes C. Integration of hemophilic boys into normal schools. Child Care Health Dev 1980; 6: 101–109. doi: 10.1111/j.1365-2214.1980.tb00802.x.
- Woolf A, Rappaport L, Reardon P, Cibrorowski J, D’Angelo E, Besette J. School functioning and disease severity in boys with hemophilia. J Dev Behav Pediatr 1989; 10: 81–85. doi/10.1097/00004703-198904000-00004.
- Olch D. Effects of hemophilia upon intellectual growth and academic achievement. J Genet Psychol 1971; 119: 63–74. doi: 10.1080/00221325.1971.10532627.
- Colgrove RW, Huntzinger RM. Academic, behavioral, and social adaptation of boys with hemophilia/HIV disease. J Pediatr Psychol 1994; 19(4): 457–73. doi: 10.1093/jpepsy/19.4.457.
- John MJ, Tanuja T, Mathew A, et al. Demographic profile and real world data of persons with hemophilia in a resource constrained setup. CHRISMED Journal of Health and Research 2018; 5: 214–20. doi: 10.4103/cjhr.cjhr_44_18.
- Dutta A, Kakati S, Kar S, Doley D. Joint and functional assessment following secondary and tertiary prophylaxis in people with hemophilia who were previously receiving episodic on demand factor replacement infrequently. Assam Journal of Internal Medicine 2020; 10(1): 27–31.
- Shapiro AD, Donfield SM, Lynn HS, et al. Defining the impact of hemophilia: the Academic Achievement in Children with Hemophilia Study. Pediatrics 2001; 108: e105.www. doi: 10.1542/peds.108.6.e105.
- Drake JH, Soucie MJ, Cutter SC, Forsberg AD, Baker JR, Riske B. High school completion rates among men with hemophilia. Am J Prev Med 2010; 38(4S): S489–S494. doi: 10.1016/j.amepre.2009.12.024.
- Feldman BM, Pai M, Rivard GE, et al. Tailored prophylaxis in severe haemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006; 4: 1228–36. 10.1111/j.1538-7836.2006.01953.x.
- Verma SP, Dutta TK, Nalini P, et al. A randomized study of very low-dose factor VIII prophylaxis in severe haemophilia – a success story from a resource limited country. Haemophilia 2016; 22: 342–8. doi: 10.1111/hae.12838.
- Sidarthan N, Sudevan R, Narayana Pillai V, et al. Low dose prophylaxis for children with haemophilia in a resource-limited setting in south India – a clinical audit report. Haemophilia 2017; 23: e382–e384. doi: 10.1111/hae.13272.
- Gouider E, Jouini L, Achour M, et al. Low dose prophylaxis in Tunisian children with haemophilia. Haemophilia 2017; 23: 77–81. doi: 10.1111/hae.13048.
- Yao et al. The efficacy of recombinant FVIII low-dose prophylaxis in Chinese pediatric patients with severe hemophilia A: a retrospective analysis from the ReCARE study. Clin Appl Thromb Hemost 2017; 23: 851–8. doi: 10.1177/1076029616679507.
- Sachdeva A, Gunasekaran V, Ramya HN, et al. Consensus statement of the Indian Academy of Pediatrics in diagnosis and management of hemophilia. Indian Pediatrics 2018; 55: 582–90. doi: 10.1007/s13312-018-1302-8.
- World Federation of Hemophilia. Report on the Annual Global Survey 2011. December 2012. Available from (accessed 28 September 2020).
- World Federation of Hemophilia. Report on the Annual Global Survey 20th Anniversary, 2018. October 2019. Available from (accessed 28 September 2020).
- Kar A, Phadnis S, Dharmarajan S, Nakade J. Epidemiology & social costs of haemophilia in India. Indian J Med Res 2014; 140(1): 19–31.